Status:
COMPLETED
Sickness Evaluation at Altitude With Acetazolamide at Relative Doses
Lead Sponsor:
Stanford University
Conditions:
Acute Mountain Sickness
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS) in travelers to ...
Detailed Description
Acute mountain sickness (AMS) is a constellation of symptoms including headache, sleep disturbance, fatigue, dizziness, and nausea, vomiting, or anorexia that commonly occurs in travelers ascending to...
Eligibility Criteria
Inclusion
- Able to complete moderate hike at altitude
- Live at elevation \< 4,000 ft
- Able to arrange own transportation to study site
- Available for full study duration (Friday night - Sunday morning)
Exclusion
- Pregnancy
- Slept at altitude \> 4,000 ft within 1 week of study
- Allergy to acetazolamide or sulfa drugs
- NSAIDs, acetazolamide, or corticosteroids within 48 hours prior to study start
- History of severe anemia, severe heart disease, advanced COPD/emphysema or sickle cell disease
Key Trial Info
Start Date :
August 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 29 2019
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT03828474
Start Date
August 9 2019
End Date
September 29 2019
Last Update
October 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
White Mountain Research Center
Bishop, California, United States, 93514